Medical Oncologist
Liver cancer treatment
Sorafenib vs Lenvatinib: — Which Is Right for Your Liver Cancer?
Both sorafenib and lenvatinib are approved for advanced liver cancer that cannot be surgically removed. They work similarly but have different side effect profiles, different costs, and each suits a slightly different patient. This page compares them directly.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Same indication, different profile — Both treat unresectable liver cancer, but their side effects, cost, and the patient populations studied in trials differ in ways that matter.
- Not simply one better than the other — The REFLECT trial found similar overall survival. Response rates favoured lenvatinib; affordability often favours sorafenib.
- Who was excluded from the trials matters — Lenvatinib was not tested in patients with main portal vein involvement. Sorafenib evidence covers a broader group.
- Generic sorafenib exists in India — Generic versions meaningfully reduce cost. Lenvatinib remains patent-protected and considerably more expensive.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Sorafenib and lenvatinib are both approved for advanced liver cancer that cannot be surgically removed. The REFLECT trial, cited by ASCO and ESMO, showed lenvatinib is non-inferior to sorafenib in overall survival and achieves a higher response rate. Which drug suits you depends on your liver function, portal vein status, and tolerance for specific side effects.
How do sorafenib and lenvatinib compare for liver cancer?
| Sorafenib (Nexavar) | Lenvatinib (Lenvima) | |
|---|---|---|
| Drug class | Oral multikinase inhibitor | Oral multikinase inhibitor |
| Dosing schedule | Twice daily | Once daily |
| Who the trials enrolled | Broader population; included patients with portal vein involvement at various levels | REFLECT trial excluded main portal vein invasion, bile duct invasion, and heavy tumour burden within the liver |
| Overall survival vs each other | Similar — lenvatinib was non-inferior (ASCO, ESMO) | Similar — non-inferior to sorafenib (ASCO, ESMO) |
| Response rate | Lower — comparator arm in REFLECT (ASCO, ESMO) | Higher than sorafenib in REFLECT (ASCO, ESMO) |
| Progression-free survival | Shorter in REFLECT | Longer than sorafenib in REFLECT (ASCO, ESMO) |
| Hand-foot skin reaction | More frequent; often needs dose adjustment | Less frequent than sorafenib |
| High blood pressure | Occurs; monitored throughout treatment | More frequent; can be pronounced — monitored closely |
| Diarrhoea | Common | Common |
| Appetite and weight loss | Mild to moderate | More pronounced; affects some patients significantly over months |
| Fatigue | Common | Common; can be marked |
| CNS activity in HCC | Not a primary differentiator — brain metastases are uncommon in liver cancer | Not a primary differentiator — brain metastases are uncommon in liver cancer |
| Generic available in India | Yes — substantially lower cost | No — brand only in most centres (as of 2025) |
| Indicative cost (India, 2025) | Lower; generic versions reduce cost significantly | Higher; brand-only pricing applies in most centres |
Which drug is my oncologist likely to recommend for me?
Both drugs are options for unresectable HCC with Child-Pugh A liver function. Your oncologist chooses based on the pattern of your disease, which trial populations your situation fits, and which side effects matter most to you.
Lenvatinib is generally preferred when portal vein involvement, bile duct invasion, and heavy tumour load within the liver are absent — those were the key exclusions from the REFLECT trial. Sorafenib's evidence base covers a broader group, including some patients with portal vein involvement.
If blood pressure is already difficult to control, sorafenib may be the safer starting point. If hand-foot skin reaction is a particular concern — for instance if you do physical work with your hands — lenvatinib's lower rate of that side effect can make a real difference to daily life.
In India, generic sorafenib is available and meaningfully lowers the monthly cost. That difference is large enough to be a legitimate part of the clinical conversation, not something to raise only if your oncologist mentions it first.
What should I tell my doctor before starting either of these drugs?
- Any blood pressure medicines you are already taking — both drugs can raise blood pressure, and the combination needs review before you start.
- Any history of bleeding problems, blood thinners, or a recent procedure — these drugs affect how blood vessels work.
- Any herbal, Ayurvedic, or traditional medicines you take by mouth — some interact with these drugs in ways that are not obvious.
- Any existing thyroid condition — lenvatinib in particular can affect thyroid function over time.
- Any heart rhythm problems or recent cardiac history.
- Whether cost is a concern — so your team can factor in the generic sorafenib option where it is clinically appropriate.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
How different is taking sorafenib from lenvatinib day to day?
Sorafenib is taken twice daily, ideally at consistent times, on an empty stomach or with a low-fat meal. Lenvatinib is taken once daily and can be taken with or without food — a simpler routine that some people find easier to maintain.
On sorafenib, hand-foot skin reaction is the side effect you are most likely to notice first — redness and tenderness on the palms and soles. Keeping skin well moisturised and avoiding tight footwear helps. Your team can reduce the dose if it becomes severe; this is a manageable and expected side effect, not a sign that the drug is harming you.
On lenvatinib, blood pressure is the side effect your team watches most closely. You may be asked to monitor it at home and call if it rises sharply. Fatigue and a reduced appetite are also common and can lead to noticeable weight loss over months of treatment.
Both drugs require regular blood tests throughout — liver function, kidney function, thyroid levels, and others. These are not optional. They are how your team catches problems early, before they become serious.
What do the medical terms on my prescription mean?
- HCC (hepatocellular carcinoma)
- The most common form of primary liver cancer, arising from liver cells. It is the form both sorafenib and lenvatinib are approved to treat.
- Child-Pugh score
- A scoring system that measures how well the liver is functioning. Most trials for these drugs enrolled patients with Child-Pugh A — meaning relatively well-preserved liver function. Your team will check this before deciding.
- Multikinase inhibitor
- A drug that blocks several different molecular signals at once. Both sorafenib and lenvatinib work this way — interfering with signals that help tumours grow and form the new blood vessels they need.
- VEGFR (vascular endothelial growth factor receptor)
- One of the main pathways both drugs target. Blocking it limits the blood supply that tumours depend on to grow.
- REFLECT trial
- A large international phase 3 trial that compared lenvatinib directly against sorafenib in advanced HCC. It is the study cited by ASCO and ESMO when recommending lenvatinib as a first-line treatment option.
- Hand-foot skin reaction
- Redness, tenderness, and thickening of skin on the palms and soles — a common side effect of sorafenib and less common with lenvatinib. It is manageable but needs to be reported early so your team can act on it.
Did you know?
Sorafenib was the first drug to extend overall survival in advanced hepatocellular carcinoma in a large randomised trial — an improvement that had eluded researchers for decades before its approval.
It remained the only approved first-line systemic option for over ten years before the REFLECT trial established lenvatinib as an alternative.
Source: ASCO Educational Resources; NCI Cancer Information
Explore 100 more Gastrointestinal & Liver Targeted Medicines topics
Drug Deep Dive: Sorafenib (Nexavar)
- Blood Pressure, Rash and Hair Thinning on Sorafenib
- Diarrhoea on Sorafenib: Controlling It Without Stopping Treatment
- Diet and Nutrition While on Sorafenib
- Drug, Food and Supplement Interactions With Sorafenib
- Fertility, Pregnancy and Contraception on Sorafenib
- Hand-Foot Skin Reaction on Sorafenib: Prevention From Day One
- How Does Sorafenib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sorafenib Take to Work?
- How Long Will You Stay on Sorafenib?
- Sorafenib (Nexavar, Soranib): The Complete Patient Guide
- Sorafenib Myths: Dose Reduction, 'Last Resort' and Generic Quality
- Sorafenib Price in India: Brand, Generic and Monthly Cost
- Sorafenib Side Effects: The Complete List and Timeline
- Sorafenib Success Rate and Survival: An Honest Look at the Numbers
- Sorafenib With Cirrhosis: Why Child-Pugh Status Decides Eligibility
- Sorafenib With TACE and Other Liver-Directed Treatments
- Sorafenib in Elderly Patients and Those With Other Illnesses
- Sorafenib in Liver, Kidney and Thyroid Cancer: Three Different Uses
- Sorafenib vs Lenvatinib for Liver Cancer: Cost, Tolerability and Evidence
- Taking Sorafenib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sorafenib
- When Sorafenib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sorafenib? Liver, Kidney and Radioiodine-Refractory Thyroid Cancer
- Will Insurance or a Government Scheme Pay for Sorafenib?
- Work, Travel and Daily Life on Sorafenib
Drug Deep Dive: Bevacizumab (Avastin)
- Avastin vs Biosimilar Bevacizumab in India: Cost and Safety
- Bevacizumab (Avastin and biosimilars): The Complete Patient Guide
- Bevacizumab Infusion Day: Premedication, Duration and What to Expect
- Bevacizumab Myths: 'It Dissolves Tumours' and Other Misconceptions
- Bevacizumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Bevacizumab Side Effects: The Complete List and Timeline
- Bevacizumab Success Rate and Survival: An Honest Look at the Numbers
- Bevacizumab With Chemotherapy: Which Combinations and Why
- Bevacizumab in Elderly Patients and Those With Other Illnesses
- Bevacizumab in Eye Disease vs Cancer: Same Drug, Very Different Dose
- Bleeding, Bowel Perforation and Wound Healing Risks on Bevacizumab
- Diet and Nutrition While on Bevacizumab
- Drug, Food and Supplement Interactions With Bevacizumab
- Fertility, Pregnancy and Contraception on Bevacizumab
- High Blood Pressure on Bevacizumab: Monitoring and Treatment
- How Does Bevacizumab Work? The Anti-VEGF Angiogenesis Inhibitor Explained
- How Long Does Bevacizumab Take to Work?
- How Long Will You Stay on Bevacizumab?
- Protein in Your Urine on Bevacizumab: What the Report Means
- Surgery While on Bevacizumab: The 28-Day Rule
- Tests and Monitoring While You Are on Bevacizumab
- When Bevacizumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Bevacizumab? Colorectal, Lung, Ovarian, Cervical and Brain Cancer
- Will Insurance or a Government Scheme Pay for Bevacizumab?
- Work, Travel and Daily Life on Bevacizumab
Drug Deep Dive: Cetuximab (Erbitux)
- Cetuximab (Erbitux): The Complete Patient Guide
- Cetuximab Infusion Day: Premedication, Duration and What to Expect
- Cetuximab Infusion Reactions: Why the First Dose Is Given Slowly
- Cetuximab Myths: 'The Worse the Rash, the Better' and Other Half-Truths
- Cetuximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Cetuximab Side Effects: The Complete List and Timeline
- Cetuximab Success Rate and Survival: An Honest Look at the Numbers
- Cetuximab With FOLFIRI, FOLFOX and Radiation
- Cetuximab in Colorectal vs Head and Neck Cancer: Different Roles
- Cetuximab in Elderly Patients and Those With Other Illnesses
- Cetuximab vs Bevacizumab in Colorectal Cancer: Which and When
- Diet and Nutrition While on Cetuximab
- Drug, Food and Supplement Interactions With Cetuximab
- Fertility, Pregnancy and Contraception on Cetuximab
- How Does Cetuximab Work? The Anti-EGFR Monoclonal Antibody Explained
- How Long Does Cetuximab Take to Work?
- How Long Will You Stay on Cetuximab?
- Low Magnesium on Cetuximab: Cramps, Fatigue and Monthly Testing
- Tests and Monitoring While You Are on Cetuximab
- The Cetuximab Rash: Severity, Treatment and Why It Predicts Response
- When Cetuximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Cetuximab? RAS Wild-Type Colorectal Cancer and Head and Neck Cancer
- Why Cetuximab Only Works in RAS Wild-Type, Left-Sided Tumours
- Will Insurance or a Government Scheme Pay for Cetuximab?
- Work, Travel and Daily Life on Cetuximab
Drug Deep Dive: Lenvatinib (Lenvima)
- Blood Pressure Spikes on Lenvatinib: The Critical First Two Weeks
- Diarrhoea, Appetite Loss and Rapid Weight Drop on Lenvatinib
- Diet and Nutrition While on Lenvatinib
- Dose Reductions on Lenvatinib: Why Most Patients Need One
- Drug, Food and Supplement Interactions With Lenvatinib
- Fertility, Pregnancy and Contraception on Lenvatinib
- Hand-Foot Skin Reaction on Lenvatinib: Prevention and Relief
- How Does Lenvatinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Lenvatinib Take to Work?
- How Long Will You Stay on Lenvatinib?
- Lenvatinib (Lenvima, Lenvanix): The Complete Patient Guide
- Lenvatinib Myths: Side Effects, Dose Cuts and 'Giving Up'
- Lenvatinib Price in India: Brand, Generic and Monthly Cost
- Lenvatinib Side Effects: The Complete List and Timeline
- Lenvatinib Success Rate and Survival: An Honest Look at the Numbers
- Lenvatinib With Immunotherapy: The Combination Explained
- Lenvatinib for Radioactive-Iodine-Refractory Thyroid Cancer
- Lenvatinib in Elderly Patients and Those With Other Illnesses
- Lenvatinib vs Sorafenib for Liver Cancer: Which Comes First?
- Taking Lenvatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Lenvatinib
- When Lenvatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Lenvatinib? Liver, Thyroid, Kidney and Endometrial Cancer
- Will Insurance or a Government Scheme Pay for Lenvatinib?
- Work, Travel and Daily Life on Lenvatinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is lenvatinib better than sorafenib for liver cancer?
They are different, not simply better or worse. The REFLECT trial, cited by ASCO and ESMO, found lenvatinib achieves a higher response rate and longer progression-free survival, while overall survival was similar between the two. Which is more appropriate depends on your specific disease pattern, liver function, tolerance for particular side effects, and cost. Your oncologist's recommendation will weigh all of those together — ask them to walk you through the reasoning behind their choice.
Can I switch from sorafenib to lenvatinib if sorafenib stops working?
These two drugs are alternatives to each other at the start of treatment, not typically used in sequence. If sorafenib stops controlling the cancer, the standard next step is usually a different second-line drug — options include regorafenib, cabozantinib, or ramucirumab depending on your situation — rather than switching to the other first-line agent. Ask your oncologist about second-line options before the current drug stops working, so you have a clear plan ready rather than deciding under pressure.
Why is lenvatinib not suitable for me if I have portal vein involvement?
The REFLECT trial that established lenvatinib's approval excluded patients with main portal vein invasion, bile duct invasion, and heavy tumour burden within the liver. Because those patients were not studied in the trial, the evidence for lenvatinib in their situation is limited and it is not approved for them. Sorafenib's original pivotal trials enrolled a broader population, making it the evidence-based first-line choice when you fall outside lenvatinib's trial criteria.
Is generic sorafenib as effective as branded Nexavar?
Generic medicines contain the same active ingredient at the same dose, and regulatory approval in India requires bioequivalence — meaning they are absorbed and work in the same way as the original branded version. The price is substantially lower. If cost is a concern, ask your oncologist or pharmacist which approved generic versions are available in your area and from a reputable supplier. The clinical outcome should be the same; the difference is in the price, not the molecule.
Are sorafenib and lenvatinib available at CION?
Yes. Both sorafenib and lenvatinib are oral medicines that can be prescribed and monitored at CION centres. Because you take them at home rather than through an infusion, your clinic visits are focused on monitoring — blood pressure checks, blood tests, dose adjustments if needed — rather than drug administration. Your oncologist will set the monitoring schedule when you start treatment.
What happens if sorafenib or lenvatinib stops working?
Second-line options are available and include regorafenib, cabozantinib, and ramucirumab, as well as checkpoint immunotherapy in selected patients. Which option is appropriate depends on which first-line drug you were on, your liver function at that point, and the current evidence for your situation. It is worth asking your oncologist about this before the current treatment stops working, so you have a plan in place and are not making decisions under pressure.